NVO Novo-Nordisk A/S SPONS ADR
Market Cap
234.25B
Dayโs Range
52W Range
Volume (3M)
1.44M
Price-Earnings Ratio
39.43
Revenue
25B
Novo-Nordisk A/S SPONS ADR Latest News



Top Discussions
4
MAY
REPORTS
Novo-Nordisk A/S SPONS ADR Q1 2023 earnings report is expected to be released before market open

NVO
Novo-Nordisk A/S SPONS ADR
136.79
4.45
(3.36%)

NVO
Novo-Nordisk A/S SPONS ADR
136.52
4.45 (3.36%)
About Novo-Nordisk A/S SPONS ADR
Novo Nordisk A/S, a healthcare company based in Bagsvรฆrd, Denmark, researches, develops, and markets pharmaceuticals. The company was founded in 1923. Novo Nordisk operates internationally through its worldwide locations.
The company operates through two segments: the Diabetes and Obesity segment provides products such as insulin, and the Biopharmaceuticals segment focuses on products such as growth disorder and hormone replacement therapies. The company is currently collaborating with Lund University regarding Parkinsonโs disease research. Novo Nordisk is listed on the NYSE under the NVO stock ticker.
Add this instrument to your eToro watchlist to receive updates and news on the NVO share price.
Show More54.3K
Employees
Bagsvรฆrd, Capital Region, US
HQ
1931
Founded
Lars Fruergaard Jรธrgensen, MBA
CEO
Upcoming Earnings
4
MAY
REPORTS
Novo-Nordisk A/S SPONS ADR Q1 2023 earnings report is expected to be released before market open
People Also Bought
- MRK Merck & Co. -0.50%
- BIIB Biogen Inc -1.35%
- DE Deere & Co -0.12%
- LLY Eli Lilly & Co 2.53%
- TMO Thermo Fisher Scientific Inc 0.12%
- NOVO-B.CO Novo Nordisk B A/S 3.66%
- VRTX Vertex Pharmaceuticals Incorporated -0.91%
- NVS Novartis ADR -0.29%